1. |
http: //www.who.int/selection_medicines/committees/expert/17/application/Amantadine_Rimantadine.pdf. 2011.10.
|
2. |
12 Guyatt GH, Oxman AD, Vist GE,
et al , GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ , 2008. 336(7650): 924-926.
|
3. |
www.cochrane-handbook.org.
|
4. |
Secretariat of WHO EXECUTIVE BOARD. WHO medicines strategy: Revised procedure for updating WHO’s Model List of Essential Drugs (EB109/8). 109th Session. 7 December 2001: 7.
|
5. |
王莉, 袁强, 成岚, 等. 我国基本药物目录遴选与评价方法的问题与反思. 中国药房, 2010, 21(16): 1453-1456.
|
6. |
WHO.The selection and use of essential medicines. Report of the WHO Expert Committee, 2009. WHO Technical Report Series, 958: 8, 31.
|
7. |
WHO. Proposal for the inclusion of Amantadine and Rimantadine in the World Health Organisation model list of essential medicines. WHO.2009, 5.
|
8. |
杨悦, 何畔, 邹韵, 等. 推荐分级的评估、制定与评价方法以及WHO在基本药物遴选中的应用. 中国药房, 2011, 22(32): 2977-2981.
|
9. |
李幼平, 王莉, 杨晓妍, 等. 我国基本药物目录制定及实施的循证思考. 中国循证医学杂志 2009, 9(11): 1131-1134.
|
10. |
肖爱丽.《国家基本药物目录》遴选与调整的思考. 中国药房, 2010, 21(12): 1072.
|
11. |
WHO. How to develop a National Essential Medicines List.who.2010, 11. http: //www.who.int/selection_medicines/committees/expert/18/How_to_developNEML_agenda_paper.pdf.2012.2.
|
12. |
曾宪涛, 田国祥, 牛玉明, 等. GRADEprofiler软件的使用简介. 中国循证心血管医学杂志, 2011, 3(5): 390-392.
|
13. |
曾宪涛, 冷卫东, 李胜, 等, 如何正确理解及使用GRADE系统. 中国循证医学杂志, 2011, 11(9): 985-990.
|
14. |
刘为民, 刘保延, 何丽云, 等. 引入GRADE体系制定中医药国际标准的思考与实践探析. 亚太传统医药, 2011, 7(1): 1-5.
|
15. |
GRADE指南: Ⅰ.导论——GRADE证据概要表和结果总结表. 中国循证医学杂志, 2011, 11(4): 437-445.
|
16. |
Gordon H. Guyatt, Andrew D. Oxman, Regina Kunz, 等. GRADE指南: Ⅱ.构建问题、确定重要结果. 中国循证医学杂志, 2011, 11(4): 446-450.
|
17. |
Howard Balshem, Mark Helfanda, Holger J. Schunemann, 等. GRADE指南: Ⅲ.证据质量分级. 中国循证医学杂志, 2011, 11(4): 451-455.
|
18. |
Gordon H. Guyatt, Andrew D. Oxman, Gunn Vist, 等. GRADE指南: Ⅳ.证据质量分级——研究的局限性(偏倚风险). 中国循证医学杂志, 2011, 11(4): 456-463.
|
19. |
Gordon H. Guyatt, Andrew D. Oxman, Victor Montori, 等. GRADE指南: Ⅴ.证据质量评价——发表偏倚. 中国循证医学杂志, 2011, 11(12): 1430-1434.
|
20. |
Gordon Guyatt, Andrew D. Oxman, Regina Kunz, 等. GRADE指南: Ⅵ.证据质量评价——不精确性(随机误差). 中国循证医学杂志, 2011, 11(12): 1435-1443.
|
21. |
Gordon H. Guyatt, Andrew D. Oxman, Regina Kunz, 等. GRADE指南: Ⅶ.证据质量评价——不一致性. 中国循证医学杂志, 2011, 11(12): 1444-1451.
|
22. |
Gordon Guyatt, Andrew D. Oxman, Regina Kunz, 等. GRADE指南: Ⅷ.证据质量评价——间接性. 中国循证医学杂志, 2011, 11(12): 1452-1458.
|
23. |
Gordon H. Guyatt, Andrew D. Oxman, Shahnaz Sultan, 等, GRADE指南: Ⅸ.证据质量升级. 中国循证医学杂志, 2011, 11(12): 1459-1463.
|
24. |
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from.
|
25. |
Guyatt GH, Oxman AD, Kunz R, et al . GRADE guidelines: 2. Framing the question and deciding on important outcomes. Clin Epidemiol , 2011, 64(4): 395-400.
|
26. |
Schünemann H, Bro?ek J, Oxman A, editors. GRADE handbook for Grading quality of evidence and strength of recommendation. 3.2 [updated March 2009]. Section 3.
|